6-K ·Filed Jul 7, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor the fireside chat for any updates on the Phase 2b/3 trial or pipeline developments. No immediate trading catalyst.
Final — all horizons settled through T+60d ⚠ clustered
OKYO ▼ -26.29% at T+60d
NEUTRAL call -26.29% · α vs SPY -28.28% · entry $1.75 → $1.29
T+1d
-5.14%
call -5.14% · α -4.83%
$1.66
settled 4mo ago
T+5d
-9.71%
call -9.71% · α -10.27%
$1.58
settled 4mo ago
T+20d
-4.57%
call -4.57% · α -5.90%
$1.67
settled 3mo ago
T+60d
-26.29%
call -26.29% · α -28.28%
$1.29
settled 28d ago
Price Chart
Loading chart...
Executive Summary
OKYO Pharma announced its participation in a fireside chat at the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The event is routine and does not involve any new material financial or clinical data.
Key Facts
- OKYO Pharma will participate in a fireside chat at the Piper Sandler 2026 Virtual Ophthalmology Symposium on July 9, 2026 at 8:30 AM ET.
- Presenters are Robert J. Dempsey (CEO) and Flavio Mantelli (CMO).
- The company recently completed a Phase 2 trial of urcosimod for neuropathic corneal pain and plans to initiate a Phase 2b/3 study in the first half of 2026.
Financial Impact
No financial impact from this filing.
Risk Factors
- Clinical trial execution risk for urcosimod Phase 2b/3 study.
- Regulatory approval risk.
- Financing risk for a clinical-stage biopharma company.
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-032253 |
| Exhibit: ex99-1.htm | 0001493152-26-032253 |
| Document: 0001493152-26-032253-index-headers.html | 0001493152-26-032253 |
| Document: 0001493152-26-032253-index.html | 0001493152-26-032253 |
| Document: 0001493152-26-032253.txt | 0001493152-26-032253 |
29 reports for OKYO
50% Hit rate @ T+1 Went positive at some point 7 of 10 best @ T+5▲ +13.89%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Showing 10 of 29
US Market Status
Market Closed — Opens Thu (10h 52m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers